United Therapeutics (NASDAQ:UTHR) & Indaptus Therapeutics (NASDAQ:INDP) Head-To-Head Comparison

United Therapeutics (NASDAQ:UTHR – Get Free Report) and Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Risk and Volatility

United Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for United Therapeutics and Indaptus Therapeutics, as provided by MarketBeat.com.

United Therapeutics presently has a consensus target price of $619.42, indicating a potential upside of 12.71%. Given United Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe United Therapeutics is more favorable than Indaptus Therapeutics.

Earnings and Valuation

This table compares United Therapeutics and Indaptus Therapeutics”s revenue, earnings per share and valuation.

United Therapeutics has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United Therapeutics and Indaptus Therapeutics’ net margins, return on equity and return on assets.

Insider & Institutional Ownership

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

United Therapeutics beats Indaptus Therapeutics on 11 of the 13 factors compared between the two stocks.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.